- Details
- Alicia Morgans is joined by Brenda Martone to discuss the transformative impact of the JAVELIN Bladder 100 trial data on the treatment of unresectable locally advanced or metastatic urothelial carcinoma. The data reveals that patients who receive maintenance avelumab post-chemotherapy experience a significant improvement in overall survival. The conversation delves into the operational aspects of...
|
- Details
- Adjuvant nivolumab could provide a treatment option for patients with muscle-invasive urothelial carcinoma to reduce the risk of recurrent cancers and death, the CheckMate 274 study finds. The standard-of-care treatment for muscle-invasive urothelial carcinoma is cisplatin-based neoadjuvant therapy followed by radical surgery. However, many patients are cisplatin-ineligible. CheckMate274 is a phas...
|
- Details
- IMvigor010 is a prospective, randomized, adjuvant trial, testing atezolizumab versus best supportive care in a high-risk bladder cancer population. Overall, the trial did not meet its progression-free survival or overall survival endpoints. Thomas Powles, MD joins Alicia Morgans, MD, MPH, highlighting the preplanned, exploratory biomarker analysis that measured ctDNA at baseline after cystectomy,...
|
- Details
- Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone. (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 trial...
|
- Details
- Ali Khaki and Petros Grivas come together to discuss three studies presented at the 2021 ASCO GU meeting, on immunotherapy in advanced urothelial carcinoma (aUC) as well as a recently published paper in this disease advanced bladder cancer which aimed to develop a prognostic model for overall survival (OS) in patients receiving first-line immune checkpoint inhibitors for advanced urothelial cancer...
|
- Details
- The analysis of the JAVELIN Bladder 100 trial, efficacy by duration or number of cycles of first-line chemotherapy presented at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) helped clinicians understand, the outcomes of avelumab from the JAVELIN 100 trial. The number of cycles (cycle every 3 weeks), of first-line chemotherapy. The optimal duration of firs...
|
- Details
- In this Journal Club, Christopher Wallis and Zachary Klaassen review the September 2020 publication The Lancet Oncology: Durvalumab Alone and Durvalumab plus Tremelimumab Versus Chemotherapy in Previously Untreated Patients with Unresectable, Locally Advanced or Metastatic Urothelial Carcinoma (DANUBE): A Randomised, Open-Label, Multicentre, Phase 3 Trial. DANUBE was conducted at 224 academic rese...
|
- Details
- Currently, the standard of care for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy. Patients with residual disease after neoadjuvant chemotherapy have an especially poor prognosis. Unfortunately, there's no standard adjuvant therapy for these patients. Andrew Lenis joins Ashish Kamat emphasizing that additional therapeutic options are needed, and understa...
|
- Details
- Cisplatin-based chemotherapy is recommended in both the neoadjuvant and the first-line setting. The inability to predict which patients would respond to chemotherapy, presents a major clinical problem, as there is a significant overtreatment of patients who do not respond. Lars Dyrskjøt joins Ashish Kamat to discuss a Nature Communications publication titled, Molecular correlates of cisplatin-base...
|
- Details
- The anti-PD-L1 avelumab in urothelial carcinoma—A discussion with investigator Dr Andrea Apolo. The JAVELIN Solid Tumor phase 1, open-label, dose-escalation trial investigated avelumab, a human monoclonal anti-PD-L1 antibody (anti-PD-L1), in patients with selected tumor indications (eg, NSCLC, breast cancer, colorectal cancer). Pooled analysis of two JAVELIN cohorts that included patients with adv...
|
